SCHEMBL7678481

SCHEMBL7678481

CCCC1C(=O)Oc2c(C)c(C(=O)c3ccc(OC)c(OC)c3)n(C)c21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.41
TSHR P16473 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
ALDH1A1 P00352 3/20 0.38
GAA P10253 1/20 0.38
PDE4B Q07343 2/20 0.37
ACHE P22303 1/20 0.37
KDM2B Q8NHM5 1/20 0.37
POLB P06746 1/20 0.36
CBX7 O95931 3/20 0.36
CDYL2 Q8N8U2 3/20 0.36
CDYL Q9Y232 3/20 0.36
CDY1; CDY1B Q9Y6F8 3/20 0.36
CTNNB1 P35222 1/20 0.36
WNT3A P56704 1/20 0.36
MAPK1 P28482 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7678168 0.92 PDE4B (0.39) CYP2C19TSHRCYP1A2CYP3A4CYP2C9
SCHEMBL7678744 0.85 TSHR (0.47) CYP2C19TSHRCYP1A2CYP3A4CYP2C9
SCHEMBL7675526 0.82 ABCB11 (0.42) CYP2C19TSHRCYP1A2CYP2C9ALDH1A1
SCHEMBL7676777 0.75 HTT (0.42) CYP2C19TSHRCYP1A2CYP2C9ALDH1A1
SCHEMBL7677090 0.73 NOD2 (0.34) KDM2B
SCHEMBL7678461 0.72 TSHR (0.47) CYP2C19TSHRCYP1A2CYP3A4CYP2C9
SCHEMBL7677005 0.71 CHRM1 (0.36) ALDH1A1KDM4ENPSR1
SCHEMBL7684691 0.68 CYP2C19 (0.46) CYP2C19TSHRCYP1A2CYP3A4CYP2C9
SCHEMBL7676850 0.67 CYP2C19 (0.48) CYP2C19TSHRCYP1A2CYP3A4CYP2C9
SCHEMBL7675544 0.67 MEN1 (0.36) TSHRALDH1A1MAPK1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6455703-B2 ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION CELL PATHWAYS, INC. 2002-09-24 US disclosed
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia OSI PHARMACEUTICALS, INC. 2001-12-13 US disclosed
US-6160003-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS, INC. (US) 2000-12-12 US disclosed
US-5939417-A 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia CELL PATHWAYS INC (US) 1999-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051651-A1 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia MALT1, VHL, CDKN1A CYP2C19 4174/4885TSHR 2892/4885CYP1A2 1487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.